Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Breccia

Showing results (11-20 of 427) with videos related to

Pageof 43
Sort By:
Expert Opinion on Investigational Drugs|January 21, 2026
ADVANCES OF NEXT-GENERATION STAMP INHIBITORS IN CHRONIC MYELOID LEUKEMIAAlessandro Costa, Massimo Breccia
Mediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIsMassimo Breccia, Giuliana Alimena
Clinical Lymphoma, Myeloma & Leukemia|April 27, 2025
SOHO State of the Art Updates and Next Questions. Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges, and Therapeutic StrategiesAlessandro Costa, Massimo Breccia
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2025
SOHO State of the Art Updates and Next Questions | Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges and Therapeutic StrategiesAlessandro Costa, Massimo Breccia
Expert Opinion on Therapeutic Targets|September 23, 2010
NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemiaMassimo Breccia, Giuliana Alimena
Cancer Letters|March 28, 2012
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantagesMassimo Breccia, Giuliana Alimena
Rare Cancers and Therapy|May 17, 2016
Bosutinib for Chronic Myeloid LeukemiaMassimo Breccia, Gianni Binotto
Annals of Hematology|February 19, 2013
Efficacy and safety of deferasirox in myelodysplastic syndromesMassimo Breccia, Giuliana Alimena
Leukemia Research|March 12, 2013
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitorsMassimo Breccia, Giuliana Alimena
Expert Review of Hematology|December 22, 2018
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemiaMassimo Breccia, Robin Foà
Pageof 43

Showing results (11-20 of 427) with videos related to

Sort By:
Pageof 43
Expert Opinion on Investigational Drugs|January 21, 2026
ADVANCES OF NEXT-GENERATION STAMP INHIBITORS IN CHRONIC MYELOID LEUKEMIAAlessandro Costa, Massimo Breccia
Mediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIsMassimo Breccia, Giuliana Alimena
Clinical Lymphoma, Myeloma & Leukemia|April 27, 2025
SOHO State of the Art Updates and Next Questions. Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges, and Therapeutic StrategiesAlessandro Costa, Massimo Breccia
Clinical Lymphoma, Myeloma & Leukemia|April 6, 2025
SOHO State of the Art Updates and Next Questions | Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges and Therapeutic StrategiesAlessandro Costa, Massimo Breccia
Expert Opinion on Therapeutic Targets|September 23, 2010
NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemiaMassimo Breccia, Giuliana Alimena
Cancer Letters|March 28, 2012
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantagesMassimo Breccia, Giuliana Alimena
Rare Cancers and Therapy|May 17, 2016
Bosutinib for Chronic Myeloid LeukemiaMassimo Breccia, Gianni Binotto
Annals of Hematology|February 19, 2013
Efficacy and safety of deferasirox in myelodysplastic syndromesMassimo Breccia, Giuliana Alimena
Leukemia Research|March 12, 2013
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitorsMassimo Breccia, Giuliana Alimena
Expert Review of Hematology|December 22, 2018
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemiaMassimo Breccia, Robin Foà
Pageof 43